PE20060332A1 - DERIVATIVES OF 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS - Google Patents
DERIVATIVES OF 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERSInfo
- Publication number
- PE20060332A1 PE20060332A1 PE2005000284A PE2005000284A PE20060332A1 PE 20060332 A1 PE20060332 A1 PE 20060332A1 PE 2005000284 A PE2005000284 A PE 2005000284A PE 2005000284 A PE2005000284 A PE 2005000284A PE 20060332 A1 PE20060332 A1 PE 20060332A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- diabetes
- naphthyridine
- naphthyridin
- phenyl
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical class C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 title 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 2
- QLESBTGTJMBIPU-UHFFFAOYSA-N 2-anilino-5-methyl-1-phenyl-1,8-naphthyridin-4-one Chemical compound C=1C(=O)C=2C(C)=CC=NC=2N(C=2C=CC=CC=2)C=1NC1=CC=CC=C1 QLESBTGTJMBIPU-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 abstract 1
- 208000004104 gestational diabetes Diseases 0.000 abstract 1
- 208000011661 metabolic syndrome X Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE 1,6-NAFTIRIDA O 1,8-NAFTIRIDA DE FORMULA I DONDE R1 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, ENTRE OTROS; R2 ES NR15R16, S(O)0-2R17, ENTRE OTROS; R15 ES H, ALQUILO C1-C6, ALQUENILO C2-C6; R16 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C6, ENTRE OTROS; R3 ES ARILO C6-C10, HETEROARILO DE 2 A 9 ATOMOS DE CARBONO Y 1 A 4 HETEROATOMOS SELECCIONADOS DE N, S(=O)0-2 Y O, ENTRE OTROS; R4 ES =O, =S Y OR21; R21 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS; R5 Y R6 SON CICLOLAQUILO C3-C8, CICLOALQUENILO C4-C8, ENTRE OTROS; R7 ES CICLOALQUILO C3-C8, CICLOALQUENILO C4-C8, ARILO C6-C10, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-ANILINO-5-METIL-1-FENIL-1,8-NAFTIRIDIN-4(1H)-ONA, 5-METIL-7-MORFOLIN-4-IL-1-FENIL-2-FENILAMINO-1H-[1,8]-NAFTIRIDIN-4-ONA, 5-METIL-1-FENIL-2,7-BIS-FENILAMINO-1H-[1,8]NAFTIRIDIN-4-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A COMPOSICIONES QUE COMPRENDEN DICHO COMPUESTO, EL CUAL ES UTIL EN EL TRATAMIENTO O PREVENCION DE LA DIABETES (TIPO 1 O 2), DIABETES JUVENIL DE INICIO EN LA MADUREZ, DIABETES AUTOINMUNE DEL ADULTO, INTOLERANCIA A LA GLUCOSA, GLUCEMIA BASAL ALTERADA, DIABETES GESTACIONAL Y SINDROME METABOLICO XREFERRING TO A COMPOUND DERIVED FROM 1,6-NAPHTHYRIDE OR 1,8-NAPHTHYRIDE OF FORMULA I WHERE R1 IS C1-C8 ALKYL, C2-C8 ALKENYL, C2-C8 ALKINYL, AMONG OTHERS; R2 IS NR15R16, S (O) 0-2R17, AMONG OTHERS; R15 IS H, C1-C6 ALKYL, C2-C6 ALKYL; R16 IS C1-C8 ALKYL, C2-C8 ALKYL, C2-C6 ALKYL, AMONG OTHERS; R3 IS C6-C10 ARYL, HETEROARYL OF 2 TO 9 CARBON ATOMS AND 1 TO 4 HETEROATOMS SELECTED FROM N, S (= O) 0-2 AND O, AMONG OTHERS; R4 IS = O, = S and OR21; R21 IS H, C1-C8 ALKYL, C2-C8 ALKYL, AMONG OTHERS; R5 AND R6 ARE C3-C8 CYCLOLAKYL, C4-C8 CYCLOALKENYL, AMONG OTHERS; R7 IS C3-C8 CYCLOALKYL, C4-C8 CYCLOALKENYL, C6-C10 ARYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE 2-ANILINO-5-METHYL-1-PHENYL-1,8-NAPHTHYRIDIN-4 (1H) -ONE, 5-METHYL-7-MORFOLIN-4-IL-1-PHENYL-2-PHENYLAMINE-1H- [1,8] -NAPHTHYRIDIN-4-ONA, 5-METHYL-1-PHENYL-2,7-BIS-PHENYLAMINE-1H- [1,8] NAPHTHYRIDIN-4-ONA, AMONG OTHERS. IT IS ALSO REFERRED TO COMPOSITIONS THAT INCLUDE SAID COMPOUND, WHICH IS USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES (TYPE 1 OR 2), JUVENILE DIABETES OF ONSET IN MATURITY, ADULT AUTOIMMUNE DIABETES, INTRODUCTION, INTRODUCTION, BASIC GLUCKAL TO ADULT , GESTATIONAL DIABETES AND METABOLIC SYNDROME X
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55297104P | 2004-03-12 | 2004-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060332A1 true PE20060332A1 (en) | 2006-06-01 |
Family
ID=35056657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000284A PE20060332A1 (en) | 2004-03-12 | 2005-03-11 | DERIVATIVES OF 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR048088A1 (en) |
| GT (1) | GT200500049A (en) |
| PE (1) | PE20060332A1 (en) |
| TW (1) | TW200538124A (en) |
| UY (1) | UY28805A1 (en) |
| WO (1) | WO2005091857A2 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009015917A2 (en) * | 2007-05-14 | 2009-02-05 | F. Hoffmann-La Roche Ag | Dihydroquinone and dihydronaphthridine inhibitors of jnk |
| PT2448938E (en) | 2009-06-29 | 2014-07-31 | Incyte Corp | Pyrimidinones as pi3k inhibitors |
| FR2952934B1 (en) * | 2009-11-23 | 2012-06-22 | Sanofi Aventis | PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| JP5816678B2 (en) | 2010-04-14 | 2015-11-18 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Condensed derivatives as PI3Kδ inhibitors |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| RU2013114390A (en) | 2010-08-31 | 2014-10-10 | СНУ Ар энд ДиБи ФАУНДЕЙШН | APPLICATION OF FETAL REPROGRAMMING BY PPAR-DELTA-AGONIST |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| BR112014000499A2 (en) * | 2011-07-12 | 2017-01-10 | Hoffmann La Roche | aminomethyl quinolone compounds |
| TWI673272B (en) | 2011-09-02 | 2019-10-01 | 美商英塞特控股公司 | Heterocyclylamines as pi3k inhibitors |
| AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| US10336759B2 (en) | 2015-02-27 | 2019-07-02 | Incyte Corporation | Salts and processes of preparing a PI3K inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2018102885A1 (en) * | 2016-12-09 | 2018-06-14 | Bionomics Limited | Modulators of nicotinic acetylcholine receptors and uses thereof |
| CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
| JOP20180097B1 (en) * | 2018-10-22 | 2023-03-28 | Univ Of Jordan | 1,8-naphthyridine gluosamine derivatives,their use in the treatment of microbial infections,and amethod for preparation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL51092A0 (en) * | 1976-12-10 | 1977-02-28 | Abic Ltd | Naphthyridine derivatives and their preparation |
| US4767762A (en) * | 1985-12-23 | 1988-08-30 | Abbott Laboratories | Tricyclic quinoline and naphthyride antibacterials |
-
2005
- 2005-02-24 WO PCT/US2005/005367 patent/WO2005091857A2/en active Application Filing
- 2005-03-10 AR ARP050100921A patent/AR048088A1/en unknown
- 2005-03-11 GT GT200500049A patent/GT200500049A/en unknown
- 2005-03-11 TW TW094107389A patent/TW200538124A/en unknown
- 2005-03-11 UY UY28805A patent/UY28805A1/en not_active Application Discontinuation
- 2005-03-11 PE PE2005000284A patent/PE20060332A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR048088A1 (en) | 2006-03-29 |
| WO2005091857A2 (en) | 2005-10-06 |
| GT200500049A (en) | 2005-10-24 |
| WO2005091857A3 (en) | 2006-10-05 |
| TW200538124A (en) | 2005-12-01 |
| UY28805A1 (en) | 2005-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060332A1 (en) | DERIVATIVES OF 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS | |
| PE20110383A1 (en) | PYRAZOLOPYRIMIDINONES AS INHIBITORS OF PHOSPHODIESTERASE 9A (PDE9A) | |
| PE20030601A1 (en) | DERIVATIVES OF 1,8-NAPHTHYRIDINE AND THEIR USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS | |
| MA32098B1 (en) | Tetrahydroquinoxaline derivatives, their preparation and application in treatment | |
| AR047972A1 (en) | DERIVED FROM BENCIMIDAZOL, PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS. | |
| CO6180449A2 (en) | QUINAZOLINONES AND NAFTIRIDINONES THAT INCLUDE A GROUP N- (BIFENIL-4-ILMETIL-N- (PIPERIDIN-4-IL) ACETAMIDE REPLACED, USEFUL FOR THE TREATMENT OF ATEROSCLEROSIS | |
| PE20090217A1 (en) | GLUCOCORTICOID MIMETIC COMPOUNDS, METHODS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS | |
| ATE388146T1 (en) | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBONIC ACID AMIDE DERIVATIVES WITH AGONISTIC EFFECT ON THE 5-HT4 RECEPTOR | |
| AR065276A1 (en) | HERBICIDES OF SUBSTITUTED PIRIDINE N-OXIDES | |
| PE20060833A1 (en) | PURINE DERIVATIVES AS AGONISTS OF THE ADENOSINE A2A RECEPTOR | |
| AR061644A1 (en) | BENZOFURAN DERIVATIVES | |
| PE20110387A1 (en) | AMINOTRIAZOLO-PYRIDINES AS KINASE INHIBITORS | |
| DK1961734T3 (en) | Amine compound and its use for medical purposes | |
| ATE556712T1 (en) | A2A ANTAGONISTS FOR THE TREATMENT OF MOTOR DISORDERS | |
| PE20230769A1 (en) | ADENOSINE A2A RECEPTOR ANTAGONISTS | |
| PE20090484A1 (en) | CALICREIN MODULATORS 7 | |
| PE20060836A1 (en) | PROCEDURES FOR PREPARING AROMATIC ETHERS | |
| ECSP088926A (en) | PIRIDIL AMIDA COMPOUNDS REPLACED AS HISTAMINE H3 RECEIVER MODULATORS | |
| PE20000134A1 (en) | ARYLPIPERAZINES THAT HAVE ACTIVITY ON THE SEROTONIN 1A RECEPTOR | |
| ATE430746T1 (en) | CRF RECEPTOR ANTAGONISTS AND ASSOCIATED METHODS | |
| NO20076402L (en) | Imaging 18F or 11C-labeled alkylthiophenyl guanidines | |
| CO5590963A2 (en) | DERIVATIVES OF AVERMECTIN B1 THAT HAVE A SUBSTITUENT OF AMINOSULPHONYLOXYL IN POSITION 4 | |
| NO20075617L (en) | 4-Phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives for the treatment of infertility | |
| AR073043A1 (en) | COMPOUNDS OF POLYSUSTITUTED AZETIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHOD OF PREPARATION AND USE OF THE SAME IN THE TREATMENT OF RESPIRATORY, METABOLIC DISEASES AND OF THE CENTRAL NERVOUS SYSTEM, AMONG OTHERS. | |
| ATE548371T1 (en) | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |